Join
Live feed
·
PRReleasevia Quantisnow
OKYO Pharma Limited logo

OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Both Sign and Symptom Endpoints in its First-in-Human Phase 2 Trial of OK-101 in Patients with Dry Eye Disease

ByQuantisnow·Wall Street's wire, on your screen.
OKYO· OKYO Pharma Limited
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track OKYO (OKYO Pharma Limited) and more on Quantisnow.